Combination of PARP inhibitor rucaparib and nivolumab in maintenance therapy after first-line ovarian cancer treatment did not significantly extend progression-free survival compared to rucaparib alone Today Nikkei Medical Oncology News (Japan, in Japanese)
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to antifibrotic drug treatments Today eCancer
Making a commitment to connect people through technology Thursday Dr. Justin Starren is a medical doctor turned data scientist who has been building bridges between people, computer systems and organizations for 30 years. Read more Image
From GenAI-powered language learning to regenerative sustainability: How innovating with design can help businesses drive progress Thursday Business Times (Singapore)
Phoenix bioscience boom poised to improve health care and local economy, proponents say Wednesday The Arizona Republic
New EDGE Learning opportunity | Spotting trouble: Understanding targeted violence Tuesday Threat Assessment and Management Team Read more